Experimental MCL drug trial halted early – what we know

NCT ID NCT06106841

Terminated Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called TQB3909 in 19 people with mantle cell lymphoma that had returned or stopped responding to treatment. The goal was to find a safe dose and check for side effects. However, the study was terminated early, so we have limited information about how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB3909 tablets (a BCL-2 inhibitor)
What this could lead to: If successful, this could provide a new treatment option for people with mantle cell lymphoma that has stopped responding to other therapies.
What could go wrong: The trial was terminated early with only 19 participants, so results are very limited. It is unclear if TQB3909 is safe or effective, and it may not work for most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Affiliated Cancer Hospital of Harbin Medical University

Harbin, Heilongjiang, 150081, China
Binzhou Medical University Hospital

Binzhou, Shandong, 256603, China
Chongqing University Hospital

Chongqing, Chongqing Municipality, 400030, China
Gansu Provincial Cancer Hospital

Lanzhou, Gansu, 730050, China
Guangxi Medical University Cancer Hospital

Nanning, Guangxi, 530021, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
Heping Hospital Affiliated to Changzhi Medical College

Changzhi, Shanxi, 046000, China
Institute of Dematology & Blood diseases Hospital

Tianjin, Tianjin Municipality, 300052, China
Jilin Cancer Hospital

Changchun, Jilin, 130012, China
Jinzhou Central Hospital

Wuxi, Jiangsu, 530031, China
Linyi People's Hospital

Linyi, Shandong, 276000, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
Shanghai Huashan Hospital

Shanghai, Shanghai Municipality, 200040, China
The Affiliated Hospital of Chengde Medical College

Chengde, Hebei, 067000, China
The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, 646000, China
The Affiliated Hospital of Xuzhou Medical University

Nanjing, Jiangsu, 220005, China
The First Affiliated Hospital Of Soochow University

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, 215006, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, 361003, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The First Hospital of Jilin University

Changchun, Jilin, 130022, China
The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 150001, China
The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215004, China
The Second Hospital of Dalian Medical University

Dalian, Liaoning, 116000, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300040, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, 430050, China
Tongji hospital of Tongji University

Shanghai, Shanghai Municipality, 200065, China
Xinjiang Uygur Autonomous Region People's Hospital

Ürümqi, Xinjiang, 830001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.